Skip to main content

Most Undervalued Stocks

These widely-followed US-listed stocks screen as inexpensive on public numbers: a trailing P/E well below the broad market, a free cash flow yield of roughly 5% or more, and in most cases a modest price-to-book ratio. Each multiple is computed from the company’s own SEC filings and the latest price on the site. Rows are ordered by a simple composite of those three measures, lowest multiple and highest cash yield first.

A low multiple usually comes with a reason. The note beside each ticker explains the concern the market is pricing in, so treat this as a list of names to research rather than a ranking of the best buys. Select any ticker for its chart, market data, and discussion.

Undervalued stocks ranked by trailing P/E, free cash flow yield, and price-to-book
#StockPriceP/EFCF yieldP/BDiv. yieldMkt cap
1$CMCSAComcast Corporation Class A Common Stock · Communication ServicesCable, broadband, and media company with large, steady free cash flow. Broadband subscriber losses to wireless and fiber rivals keep investors cautious.$22.137.125.9%0.96.0%$79B
2$TAT&T Inc. · Communication ServicesTelecom carrier that has refocused on wireless and fiber after selling its media businesses. Debt reduction is the story; growth is slow and the dividend was cut in 2022.$25.458.411.3%1.44.4%$174B
3$CIThe Cigna Group Common Stock · Health CareHealth insurer and pharmacy benefit manager with strong cash generation. Policy scrutiny of benefit managers and rising medical costs across the industry hold the multiple down.$265.5011.013.2%1.62.3%$70B
4$GMGeneral Motors Company Common Stock · Consumer DiscretionaryAutomaker with a low price-to-book ratio and strong cash generation. Large one-time charges in late 2025 depress trailing reported earnings, so the trailing P/E looks higher than the multiple on adjusted or forward earnings that is usually quoted. Investors discount cyclical demand, tariffs, and the cost of the electric vehicle transition.$80.5736.020.4%1.10.8%$71B
5$KHCThe Kraft Heinz Company Common Stock · Consumer StaplesPackaged-food maker that has traded below book value. Flat volumes, private-label competition, and a planned split of the company leave the market waiting for proof of growth.$23.86n/a13.5%0.86.7%$28B
6$VZVerizon Communications Inc. Common Stock · Communication ServicesWireless and broadband carrier with steady cash flow and a heavy debt load. Slow subscriber growth and price competition keep the multiple low.$47.3212.311.1%1.95.9%$197B
7$CVSCVS Health Corporation Common Stock · Health CarePharmacy, insurer, and pharmacy benefit manager in one company. Medical cost pressure at the Aetna insurance unit and regulatory scrutiny of benefit managers weigh on the valuation.$85.0522.410.8%1.43.1%$109B
8$FFord Motor Company Common Stock · Consumer DiscretionaryAutomaker with a profitable truck and commercial business and a loss-making electric vehicle unit. Warranty costs, tariffs, and EV losses explain the low multiple.$12.60n/a18.6%1.44.8%$51B
9$CCitigroup Inc. Common Stock · FinancialsGlobal bank that has traded near or below book value while it works through a multi-year restructuring. Returns on equity trail peers, which is the main reason for the discount.$132.1018.9n/a1.11.8%$231B
10$BMYBristol-Myers Squibb Company Common Stock · Health CareDrugmaker with strong cash generation and a low earnings multiple. Key products lose exclusivity over the next several years, and the market is unsure newer launches will fill the gap.$61.5013.59.1%5.64.1%$126B
11$MOAltria Group Inc. · Consumer StaplesTobacco company with high cash flow and a high dividend. Cigarette volumes decline every year and the balance sheet shows negative book value, so the low multiple reflects a shrinking core business.$68.8814.57.9%n/a6.2%$115B
12$CVXChevron Corporation Common Stock · EnergyIntegrated oil and gas producer with a long dividend record. The multiple moves with oil prices, and the long-term demand outlook for fossil fuels caps how much investors will pay.$205.6519.86.6%2.13.4%$406B
13$PFEPfizer Inc. Common Stock · Health CarePharmaceutical maker whose earnings reset after COVID-era vaccine sales faded. The market is pricing in patent expirations later this decade and questions about the pipeline that replaces them.$28.4137.46.8%1.96.1%$162B

Earnings, free cash flow, book value, and dividends per share are taken from each company’s annual and quarterly reports filed with the SEC over the trailing twelve months (every row reflects filings through at least December 31, 2025, last refreshed September 23, 2026). Multiples are computed from the most recent end-of-day price. “n/a” means the measure is negative or not meaningful, for example when a company has no trailing profit, negative book value, or is a bank, where operating cash flow is not a useful free cash flow measure. See data sources for how figures are gathered and how to research a stock before buying for what to check next.

Frequently Asked Questions

What does undervalued mean here?
A stock is listed when its share price is low relative to what the business earns and the cash it generates: a trailing P/E well under the broad market, a free cash flow yield of roughly 5% or more, and in most cases a modest price-to-book ratio. It is a screen based on public numbers, not a judgment that the price is wrong.
Why is a low P/E not automatically a bargain?
The market usually has a reason to pay less. Patent expirations, falling volumes, heavy debt, or cyclical earnings can all make a low multiple fair rather than cheap. Each row includes a short note on the concern behind the number so you can research it yourself.
How often are the figures updated?
The per-share figures behind each multiple come from the company’s own annual and quarterly reports filed with the SEC and are refreshed after each earnings season. Each multiple is then computed from the most recent end-of-day price on the site, so the P/E shown always matches the price beside it. The filing period each row reflects is shown at the bottom of the table.